Z. Chi

发表

An Evidence-Based Staging System for Mucosal Melanoma: A Proposal

J. Gershenwald, C. Balch, Li Zhou, 2022, Annals of Surgical Oncology.

Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma

C. Cui, B. Lian, L. Si, 2013, Clinical Cancer Research.

Gene expression screening identifies CDCA5 as a potential therapeutic target in acral melanoma.

C. Cui, L. Si, Z. Chi, 2018, Human Pathology.

Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma.

Li Zhou, X. Bai, C. Cui, 2022, Clinical genitourinary cancer.

Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials

Li Zhou, X. Bai, C. Cui, 2021, Frontiers in Immunology.

Identification of a functional polymorphism within the 3'-untranslated region of denticleless E3 ubiquitin protein ligase homolog associated with survival in acral melanoma.

Jinyu Yu, C. Cui, L. Si, 2019, European journal of cancer.

Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy

C. Cui, B. Lian, L. Si, 2017, Clinical Cancer Research.

Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients

C. Cui, B. Lian, L. Si, 2015, British Journal of Ophthalmology.

An Evidence-Based Staging System for Mucosal Melanoma: A Proposal

J. Gershenwald, C. Balch, Li Zhou, 2022, Annals of Surgical Oncology.

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Haifeng Song, Jinwei Hu, Li Zhou, 2019, Journal of Hematology & Oncology.

Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy

Li Zhou, X. Bai, C. Cui, 2020, Translational oncology.

Real-world analysis of clinicopathological characteristics, survival rates, and prognostic factors in patients with melanoma brain metastases in China

Li Zhou, X. Bai, C. Cui, 2021, Journal of Cancer Research and Clinical Oncology.

A phase II study of fotemustine plus dacarbazine with dendritic cell vaccines as first-line therapy for Chinese patients with advanced acral lentiginous melanoma

C. Cui, L. Si, Z. Chi, 2009 .

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Jiyan Liu, J. Ying, X. Yao, 2020, Clinical Cancer Research.

Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study

Qing Yang, Li Zhou, X. Bai, 2022, BMC Cancer.

Increased AURKA Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma

C. Cui, L. Si, Z. Chi, 2018, Journal of Cancer.

Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma.

Xu Li, Li Zhou, X. Bai, 2020, Urologic oncology.

Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study.

F. Zhou, Jianlin Yuan, Q. Wei, 2018, European journal of cancer.

Surgical Outcomes of Vaginal or Cervical Melanoma

Li Zhou, X. Bai, Lingying Wu, 2022, Frontiers in Surgery.

Toripalimab (anti-PD-1) versus High-Dose Interferon-α2b as Adjuvant Therapy in Resected Mucosal Melanoma: A Phase II Randomized Trial.

K. Li, X. Bai, C. Cui, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure1

Li Zhou, X. Bai, C. Cui, 2018, Translational oncology.

Potential Mutations in Uveal Melanoma Identified Using Targeted Next-Generation Sequencing

Jinyu Yu, Ting Yin, C. Cui, 2019, Journal of Cancer.

Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy

Li Zhou, X. Bai, C. Cui, 2022, Melanoma research.

Methylation of O6-methylguanine DNA methyltransferase promoter is a predictive biomarker in Chinese melanoma patients treated with alkylating agents

L. Si, Z. Chi, X. Sheng, 2018, Translational Cancer Research.

TERT copy gain predicts the outcome of high-dose interferon α-2b therapy in acral melanoma

J. Dai, C. Cui, L. Si, 2018, OncoTargets and therapy.

Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition).

W. Wei, K. Nan, Jun Liang, 2016, Chinese clinical oncology.

Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition).

W. Wei, K. Nan, Jun Liang, 2015, Annals of translational medicine.

Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.

K. Flaherty, Xiaowei Xu, C. Cui, 2012, European journal of cancer.

Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy—Ad hoc Analyses of Pooled Data From Two Clinical Trials

Li Zhou, X. Bai, C. Cui, 2021, Frontiers in Oncology.

Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma

K. Flaherty, C. Corless, Xiaowei Xu, 2011, Clinical Cancer Research.

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

K. Flaherty, C. Corless, Xiaowei Xu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma

K. Flaherty, Jinyu Yu, Li Zhou, 2019, Clinical Cancer Research.

RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma

C. Cui, L. Si, Z. Chi, 2019, Cell Death & Disease.

Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients

C. Cui, L. Si, Z. Chi, 2018, Journal of Hematology & Oncology.

Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor.

K. Brown, X. Bai, C. Cui, 2018, European journal of cancer.

Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma

Jinyu Yu, Wenxian Yang, Rongshan Yu, 2021, npj Genomic Medicine.

Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma

Jinyu Yu, Wengang Zhou, Wenxian Yang, 2020, bioRxiv.

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma

C. Cui, L. Si, Z. Chi, 2014, BMC Cancer.

Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway.

Li Zhou, X. Bai, C. Cui, 2021, European journal of cancer.

Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Xiaowei Xu, C. Cui, L. Si, 2015, Clinical Cancer Research.

Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon

C. Cui, L. Si, Z. Chi, 2017, Translational oncology.

PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro

C. Cui, L. Si, Z. Chi, 2018, Cancer biology & therapy.

Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma.

Li Zhou, X. Bai, C. Cui, 2022, Clinical genitourinary cancer.

Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma

Li Zhou, X. Bai, C. Cui, 2020, EBioMedicine.

Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy

Zelong Xu, Li Zhou, X. Bai, 2023, Journal for ImmunoTherapy of Cancer.

Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Xiaowei Xu, Ruifeng Yang, Shujing Liu, 2013, Clinical Cancer Research.

Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy

Siming Li, C. Cui, B. Lian, 2017, Journal of Translational Medicine.

MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases

Li Zhou, X. Bai, C. Cui, 2017, Clinical Cancer Research.

Analysis of TSC1 mutation spectrum in mucosal melanoma

C. Cui, L. Si, Z. Chi, 2018, Journal of Cancer Research and Clinical Oncology.

Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study

H. Pan, Qian Tan, Z. Zou, 2023, BMC Cancer.

Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in China: retrospective, observational study

A. Deitz, Li Zhou, X. Bai, 2019, International Journal of Surgery: Oncology.

MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways

Li Zhou, X. Bai, C. Cui, 2019, Theranostics.

Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma

C. Cui, L. Si, Z. Chi, 2017, Oncology letters.

A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma.

Li Zhou, X. Bai, C. Cui, 2019 .

Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy.

Li Zhou, X. Bai, Lizhi Shao, 2022, The British journal of dermatology.

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases

C. Cui, L. Si, Z. Chi, 2011, BMC Cancer.

Analysis of overall survival (OS) and relapse-free-survival (RFS) in the phase 1b clinical trial of anti–PD-1 ab (toripalimab) plus intralesional injection of OrienX010 in stage Ⅳ melanoma with liver metastases.

Yue Yang, Li Zhou, X. Bai, 2022, Journal of Clinical Oncology.

The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies

Li Zhou, X. Bai, C. Cui, 2020, Frontiers in Oncology.

Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial

Haifeng Song, Jing Chen, Weifeng Wang, 2020, Clinical Cancer Research.

OrienX010 oncolytic viral therapy in phase Ic trial of intralesional injection in liver metastases among patients with stage IV melanoma after standard treatment.

Li Zhou, X. Bai, C. Cui, 2017 .

OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study

Li Zhou, X. Bai, C. Cui, 2022, Journal for ImmunoTherapy of Cancer.

A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients.

C. Cui, L. Si, Z. Chi, 2011, European journal of cancer.

High G2 and S‐phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis

C. Cui, L. Si, Z. Chi, 2018, Cancer science.

Response to sunitinib in Chinese KIT-mutated metastatic mucosal melanoma.

L. Shen, C. Cui, L. Si, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study

Li Zhou, X. Bai, C. Cui, 2019, Oncology research.

Intra-arterial hepatic bio-chemotherapy for the treatment of melanoma patients with liver metastasis: A phase II clinical study.

L. Shen, Lin Shen, C. Cui, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial

Li Zhou, Yun Fan, X. Bai, 2021, Frontiers in Oncology.

Clinical significance of BRAFV600E mutation in circulating tumor DNA in Chinese patients with melanoma.

C. Cui, L. Si, Z. Chi, 2017, Oncology letters.

BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma.

S. Li, X. Bai, C. Cui, 2017, Neoplasma.

A phase 2 clinical trial of neoadjuvant anti-PD-1 ab (Toripalimab) plus axitinib in resectable mucosal melanoma.

Li Zhou, X. Bai, C. Cui, 2021 .

Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial

K. Flaherty, Xiongwen Tang, Li Zhou, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients

C. Balch, Li Zhou, S. Li, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma.

Li Zhou, X. Bai, C. Cui, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies

Li Zhou, X. Bai, C. Cui, 2021, Frontiers in Pharmacology.

Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study

Hang Li, X. Bai, C. Cui, 2022, The British journal of dermatology.

Toripalimab for the treatment of melanoma

Z. Chi, B. Tang, Jun Guo, 2020, Expert opinion on biological therapy.

The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma

C. Balch, Li Zhou, Hang Li, 2020, Annals of Surgical Oncology.

Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China

C. Cui, B. Lian, L. Si, 2018, Annals of Surgical Oncology.

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis

K. Flaherty, Xiongwen Tang, Li Zhou, 2022, Journal for ImmunoTherapy of Cancer.

Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients

C. Cui, B. Lian, L. Si, 2019, Thoracic cancer.

GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis.

C. Cui, B. Lian, L. Si, 2016, European journal of cancer.

Establishment and characterization of melanoma patient-derived xenograft models for preclinical evaluation of novel therapeutics

C. Cui, L. Si, Z. Chi, 2018, Melanoma research.

cMET-N375S germline mutation is associated with poor prognosis of melanoma in Chinese patients

C. Cui, L. Si, Z. Chi, 2018 .

Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients

C. Balch, X. Bai, C. Cui, 2018, Annals of Surgical Oncology.

Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma.

Li Zhou, X. Bai, C. Cui, 2021, European journal of cancer.

Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report.

Li Zhou, X. Bai, C. Cui, 2018, Chinese clinical oncology.

A phase II study of JS001, a humanized PD-1 mAb, in patients with advanced melanoma in China.

J. Chen, S. Qin, C. Cui, 2018 .

Preliminary results from patients with metastatic urothelial carcinoma (UC) in a phase 2 study of JS001, an anti-PD-1 monoclonal antibody.

C. Cui, L. Si, Z. Chi, 2018 .

A phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic mucosal melanoma.

Li Zhou, X. Bai, C. Cui, 2018 .

Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I-III.

Yang Wang, Yang Wang, Li Zhou, 2022, European journal of cancer.

A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma.

M. Tao, S. Qin, K. Gu, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma

Jing Fang, Lu Si, Shan Wu, 2017, Scientific Reports.

Major response to everolimus in melanoma with acquired imatinib resistance.

K. Flaherty, Xiaowei Xu, Weiwei Yu, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma

Li Zhou, Y. Lai, X. Bai, 2022, Frontiers in Oncology.

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis

C. Cui, B. Lian, L. Si, 2016, Oncotarget.

miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy

C. Cui, L. Si, Z. Chi, 2019, Journal of experimental & clinical cancer research : CR.

HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population

Li Zhou, X. Bai, C. Cui, 2023, The oncologist.

Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer

J. Ying, Yanxia Shi, Y. Ling, 2023, Journal of the National Cancer Center.

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors

D. Ye, Hai-Liang Zhang, Xuesong Li, 2017, BMC Cancer.

Study RC48-C014: Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma.

Hongqian Guo, Li Zhou, X. Bai, 2022, Journal of Clinical Oncology.

Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma.

D. Cao, Li Zhou, Yi-qiang Liu, 2022, Urologic oncology.

Adjuvant anti-PD-1 ab (Toripalimab) versus high-dose IFN-a2b in resected mucosal melanoma: A phase randomized trial.

Li Zhou, X. Bai, C. Cui, 2021 .

Phase III randomized, multicenter trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma.

Li Zhou, X. Bai, C. Cui, 2018 .

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors

D. Ye, Hai-Liang Zhang, Xuesong Li, 2017, BMC Cancer.

A Functional Synonymous Variant in PDGFRA Is Associated with Better Survival in Acral Melanoma

Li Zhou, X. Bai, C. Cui, 2020, Journal of Cancer.

EZH2 inhibitor enhances the STING agonist-induced antitumor immunity in melanoma.

C. Cui, L. Si, Z. Chi, 2021, The Journal of investigative dermatology.

Anti-VEGFR, PDGFR, and CSF1R tyrosine kinase inhibitor CM082 (X-82) in combination with everolimus for treatment of metastatic renal cell carcinoma: a phase 1 clinical trial

Li Zhou, X. Bai, C. Cui, 2017 .

Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial.

Yue Yang, Li Zhou, X. Bai, 2023, JAMA oncology.

Durable response of the triple combination of temozolomide, sorafenib, and bevacizumab as second-line therapy for patients with stage IV acral melanoma.

L. Shen, C. Cui, L. Si, 2009, Journal of Clinical Oncology.

Endostatin combined with chemotherapy as first-line therapy for stage IV melanoma patients: A phase II clinical study.

L. Shen, C. Cui, L. Si, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized, open-label, multi-center phase II study to compare bevacizumab plus sorafenib versus sorafenib for the third-line treatment of patients with metastatic renal cell carcinoma (NCT02330783).

F. Zhou, D. Ye, Zhi-song He, 2015 .

[A pilot study of sunitinib as first-line therapy for metastatic renal cell carcinoma on a 2 weeks on/1 week off intermittent dosing schedule].

C. Cui, B. Lian, L. Si, 2015, Zhonghua zhong liu za zhi [Chinese journal of oncology].

A pilot, open-label phase II study of sorafenib combined with cisplatin plus gemcitabine for the treatment of patients with advanced renal collecting duct carcinoma.

F. Zhou, Jianlin Yuan, Q. Wei, 2014 .

Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial.

Yue Yang, Li Zhou, X. Bai, 2023, European journal of cancer.

404O The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients from china

C. Balch, L. Zhou, C. Cui, 2016 .

RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib/II study.

Li Zhou, X. Bai, C. Cui, 2021 .

Clinicopathologic features of Xp11.2 translocation renal cell carcinoma and its response to target therapy.

Li Zhou, X. Bai, C. Cui, 2021 .

miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy

C. Cui, L. Si, Z. Chi, 2019, Journal of Experimental & Clinical Cancer Research.

A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma

M. Tao, S. Qin, K. Gu, 2013 .

Phase II randomized study of high-dose interferon alfa-2b (HDI) versus chemotherapy as adjuvant therapy in patients with resected mucosal melanoma.

C. Cui, B. Lian, L. Si, 2012 .

A phase II randomized study of adjuvant imatinib versus high-dose interferon alpha-2b for resected high-risk c-kit mutated melanoma.

C. Cui, B. Lian, L. Si, 2013 .

A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma.

M. Tao, S. Qin, K. Gu, 2013, Molecular Therapy.

Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China

C. Cui, B. Lian, L. Si, 2018, Annals of Surgical Oncology.

Phase Ib study of anlotinib in combination with anti‐PD‐L1 antibody (TQB2450) in patients with advanced acral melanoma

Li Zhou, X. Bai, C. Cui, 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.

RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma

C. Cui, L. Si, Z. Chi, 2019, Cell Death & Disease.

Durable response of the triple combination of temozolomide, sorafenib, and bevacizumab to treat refractory stage IV acral melanoma.

C. Cui, L. Si, Z. Chi, 2010 .